Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 16-18 April 2024

Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Cyramza, ramucirumab, Date of authorisation: 19/12/2014, Revision: 17, Status: Authorised

Industry Update webinar on Regulatory Procedure Management for Product Lifecycle Management on IRI, Online, European Medicines Agency, Amsterdam, the Netherlands, from 13 June 2024, 10:00 (CEST) to 13 June 2024, 11:30 (CEST)

Network Update webinar on Regulatory Procedure Management for Product Lifecycle Management on IRIS, Online, European Medicines Agency, Amsterdam, the Netherlands, from 18 June 2024, 10:00 (CEST) to 18 June 2024, 11:30 (CEST)

Veterinary medicines European public assessment report (EPAR): Respivac TRT, Turkey rhinotracheitis virus, strain 1062, live, Status: Opinion

Annex II to the call for proposals - Vendor financial identification form

Product Management Service (PMS) Product UI and API training (access & navigation), Online, European Medicines Agency, Amsterdam, the Netherlands, from 3 June 2024, 10:00 (CEST) to 3 June 2024, 11:30 (CEST)

EMA multi-stakeholder workshop on psychedelics – Towards an EU regulatory framework, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 16 April 2024, 13:00 (CEST) to 17 April 2024, 16:00 (CEST)

Committee for Medicinal Products for Human Use (CHMP): 19-22 February 2024, European Medicines Agency, Amsterdam, the Netherlands, from 19 February 2024 to 22 February 2024